AnaptysBio Inc Stock
AnaptysBio Inc Stock
AnaptysBio Inc shows a slight decrease today, losing -€0.200 (-0.890%) compared to yesterday.
We see a rather positive sentiment for AnaptysBio Inc with 8 Buy predictions and 1 Sell predictions.
With a target price of 45 € there is potential for a 102.7% increase which would mean more than doubling the current price of 22.2 € for AnaptysBio Inc.
Pros and Cons of AnaptysBio Inc in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of AnaptysBio Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
AnaptysBio Inc | -0.890% | 2.778% | -5.128% | 29.825% | 14.433% | 11.558% | - |
Immunic Inc. | 1.340% | -2.275% | -2.531% | -23.910% | -21.888% | -89.991% | - |
NanoViricides Inc. | 0.850% | -0.840% | 39.645% | 140.816% | 149.735% | -28.830% | -41.958% |
Synthetic Biologics Inc. | 8.990% | -0.626% | -32.290% | -63.101% | -40.500% | -95.551% | -94.591% |
Comments
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
Show more
Ratings data for ANAB provided by MarketBeat
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
Show more
Ratings data for ANAB provided by MarketBeat
News
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week
Many stocks were wobbly over the past few trading days, but we can't say that about biotech AnaptysBio (NASDAQ: ANAB). The company's shares closed the week almost 8% higher in price, according to